Page 4«..3456..1020..»

Change of management

By Dr. Matthew Watson

Please read the full announcement in PDF

View post:
Change of management

To Read More: Change of management
categoriaGlobal News Feed commentoComments Off on Change of management | dataNovember 26th, 2020
Read All

BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020

By Dr. Matthew Watson

MISSISSAUGA, Ontario, Nov. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2020. Key highlights include:

See original here:
BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020

To Read More: BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020
categoriaGlobal News Feed commentoComments Off on BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020 | dataNovember 26th, 2020
Read All

On “Grindeks” results in the first nine months of 2020

By Dr. Matthew Watson

On “Grindeks” results in the first nine months of 2020

View original post here:
On “Grindeks” results in the first nine months of 2020

To Read More: On “Grindeks” results in the first nine months of 2020
categoriaGlobal News Feed commentoComments Off on On “Grindeks” results in the first nine months of 2020 | dataNovember 26th, 2020
Read All

Notification of Managers’ transactions

By Dr. Matthew Watson

Company announcement no. 48 - 20 26 November 2020

Continue reading here:
Notification of Managers’ transactions

To Read More: Notification of Managers’ transactions
categoriaGlobal News Feed commentoComments Off on Notification of Managers’ transactions | dataNovember 26th, 2020
Read All

Saniona AB’s Nomination Committee for the Annual General Meeting 2021

By Dr. Matthew Watson

PRESS RELEASE

Follow this link:
Saniona AB’s Nomination Committee for the Annual General Meeting 2021

To Read More: Saniona AB’s Nomination Committee for the Annual General Meeting 2021
categoriaGlobal News Feed commentoComments Off on Saniona AB’s Nomination Committee for the Annual General Meeting 2021 | dataNovember 26th, 2020
Read All

Kane Biotech Announces Third Quarter 2020 Financial Results

By Dr. Matthew Watson

WINNIPEG, Manitoba, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced their third quarter 2020 financial results.

Here is the original post:
Kane Biotech Announces Third Quarter 2020 Financial Results

To Read More: Kane Biotech Announces Third Quarter 2020 Financial Results
categoriaGlobal News Feed commentoComments Off on Kane Biotech Announces Third Quarter 2020 Financial Results | dataNovember 26th, 2020
Read All

Eve & Co Announces Financial Results for the Three and Nine Months Ended September 30, 2020

By Dr. Matthew Watson

STRATHROY, Ontario, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce its financial results for the three and nine months ended September 30, 2020. The financial statements and management’s discussion and analysis for such period are available on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com and on Eve & Co's website at www.evecannabis.ca.

Read the rest here:
Eve & Co Announces Financial Results for the Three and Nine Months Ended September 30, 2020

To Read More: Eve & Co Announces Financial Results for the Three and Nine Months Ended September 30, 2020
categoriaGlobal News Feed commentoComments Off on Eve & Co Announces Financial Results for the Three and Nine Months Ended September 30, 2020 | dataNovember 26th, 2020
Read All

Braingrid Limited Announces Changes to Board of Directors

By Dr. Matthew Watson

TORONTO, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Braingrid Limited (CSE: BGRD) (“Braingrid” or the “Company”) is pleased to announce that Gregory Pepin has been appointed to the Company’s Board of Directors.

See more here:
Braingrid Limited Announces Changes to Board of Directors

To Read More: Braingrid Limited Announces Changes to Board of Directors
categoriaGlobal News Feed commentoComments Off on Braingrid Limited Announces Changes to Board of Directors | dataNovember 26th, 2020
Read All

EXMceuticals Provides Bi-Weekly Default Status Report

By Dr. Matthew Watson

VANCOUVER, British Columbia, Nov. 26, 2020 (GLOBE NEWSWIRE) -- EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”) is providing this bi-weekly default status report in accordance with National Policy 12-203 Management Cease Trade Orders (“NP 12-203”). On October 23, 2020, the Company announced that, for reasons set out in its news release of October 23, 2020, the filing of its annual audited financial statements for the year ended June 30, 2020, the accompanying management’s discussion and analysis and the related CEO and CFO certifications (collectively, the “Annual Filings”) would not be filed by the prescribed deadline of October 28, 2020.

See the rest here:
EXMceuticals Provides Bi-Weekly Default Status Report

To Read More: EXMceuticals Provides Bi-Weekly Default Status Report
categoriaGlobal News Feed commentoComments Off on EXMceuticals Provides Bi-Weekly Default Status Report | dataNovember 26th, 2020
Read All

Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

By Dr. Matthew Watson

BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced that management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 12:35 p.m. ET.

See the original post:
Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

To Read More: Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
categoriaGlobal News Feed commentoComments Off on Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference | dataNovember 25th, 2020
Read All

Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020

By Dr. Matthew Watson

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 at 2:00 p.m. ET.

See the rest here:
Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020

To Read More: Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020
categoriaGlobal News Feed commentoComments Off on Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 | dataNovember 25th, 2020
Read All

Arvinas to Participate in Upcoming Virtual Investor Conferences

By Dr. Matthew Watson

NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences:

Read the original post:
Arvinas to Participate in Upcoming Virtual Investor Conferences

To Read More: Arvinas to Participate in Upcoming Virtual Investor Conferences
categoriaGlobal News Feed commentoComments Off on Arvinas to Participate in Upcoming Virtual Investor Conferences | dataNovember 25th, 2020
Read All

Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

By Dr. Matthew Watson

COPENHAGEN, Denmark, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 3, 2020. Company executives will provide a business overview and update on the company’s pipeline programs.

Read this article:
Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

To Read More: Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
categoriaGlobal News Feed commentoComments Off on Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference | dataNovember 25th, 2020
Read All

Radient Technologies Announces partnership with US based Dreamy CBD

By Dr. Matthew Watson

EDMONTON, Alberta, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), is pleased to announce a licensing agreement with Dreamy Co., (“Dreamy”) to bring in Dreamy CBD products under Radient’s platform to Canada and extend it to other international markets. Initially founded in the US, Dreamy has developed a lifestyle brand over the past decade focused on the Health and Wellness space before branching into the CBD vertical. Dreamy is focused on creating and inspiring people to use plant medicine and holistic healing in place of conventional pharmaceutical solutions. In the US, Dreamy CBD enjoys a strong presence in California, and the Dreamy brand has a strong association with a positive lifestyle in the rapidly growing Wellness space. The Dreamy CBD products comprise CBD tinctures, CBD distillates, CBD edibles, CBD cosmetics, and CBD Vape Cartridges geared towards the recreational and medical cannabis market.

See the original post here:
Radient Technologies Announces partnership with US based Dreamy CBD

To Read More: Radient Technologies Announces partnership with US based Dreamy CBD
categoriaGlobal News Feed commentoComments Off on Radient Technologies Announces partnership with US based Dreamy CBD | dataNovember 25th, 2020
Read All

AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020

By Dr. Matthew Watson

SAN JOSE, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its cancer screening tests and set a record in paid test volume in the third quarter. With a strong fourth quarter already underway, the Company forecasts a revenue growth of approximately 100% in 2020 over 2019, with a revenue range of US$3 million (~ RMB20 million) to US$3.3 million (~ RMB22 million). For 2019, the Company had a revenue of US$1.6 million (~ RMB10.9 million) (using a current US$ to RMB exchange ratio of ~ 6.6). We expect the strong momentum of YoY revenue growth due to market demand and customers accepting AnPac Bio’s novel cancer screening technology with multiple advantages (named cancer differentiation analysis (CDA) technology)) to continue into 2021. The Company plans to release its full year 2020 audited financial report in early March 2021.

More:
AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020

To Read More: AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020
categoriaGlobal News Feed commentoComments Off on AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020 | dataNovember 25th, 2020
Read All

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies

By Dr. Matthew Watson

MAINZ, Germany and LONDON, United Kingdom, November 25, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd today announced a multi-year strategic collaboration aimed at applying the latest advances in artificial intelligence (AI) and machine learning (ML) technology to develop novel immunotherapies for a range of cancers and infectious diseases.

More:
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies

To Read More: BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies
categoriaGlobal News Feed commentoComments Off on BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies | dataNovember 25th, 2020
Read All

Tauriga Sciences, Inc. Officially Transitions its E-Commerce Payment Processing to Square Inc. & is Now Approved to Accept American Express Credit…

By Dr. Matthew Watson

See the rest here:
Tauriga Sciences, Inc. Officially Transitions its E-Commerce Payment Processing to Square Inc. & is Now Approved to Accept American Express Credit...

To Read More: Tauriga Sciences, Inc. Officially Transitions its E-Commerce Payment Processing to Square Inc. & is Now Approved to Accept American Express Credit…
categoriaGlobal News Feed commentoComments Off on Tauriga Sciences, Inc. Officially Transitions its E-Commerce Payment Processing to Square Inc. & is Now Approved to Accept American Express Credit… | dataNovember 25th, 2020
Read All

Equillium Provides Itolizumab COVID-19 Program Update

By Dr. Matthew Watson

Analyst Day scheduled for December 4, 2020 Analyst Day scheduled for December 4, 2020

Here is the original post:
Equillium Provides Itolizumab COVID-19 Program Update

To Read More: Equillium Provides Itolizumab COVID-19 Program Update
categoriaGlobal News Feed commentoComments Off on Equillium Provides Itolizumab COVID-19 Program Update | dataNovember 25th, 2020
Read All

Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference

By Dr. Matthew Watson

FORT LAUDERDALE, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate in the Piper Sandler 32nd Annual Healthcare Conference, which is scheduled to take place virtually from December 1-3, 2020.

See the original post here:
Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference

To Read More: Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference | dataNovember 25th, 2020
Read All

Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) – 3 years ISO 9001-2015 certification successfully obtained

By Dr. Matthew Watson

Loos, France, Isovital Headquarter, Nov 24th 2020 - Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) - 3 years ISO 9001-2015 certification successfully obtained for the “National, international distribution and logistics of cooled pharmaceutical, biological, diagnostic and radioactive products”.

View original post here:
Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) - 3 years ISO 9001-2015 certification successfully obtained

To Read More: Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) – 3 years ISO 9001-2015 certification successfully obtained
categoriaGlobal News Feed commentoComments Off on Radiopharma Logistics Group (RLG) ; ISOTOPES SERVICES INTERNATIONAL (ISI) – 3 years ISO 9001-2015 certification successfully obtained | dataNovember 25th, 2020
Read All

Page 4«..3456..1020..»